Chesley Taft & Associates LLC Biogen Inc. Transaction History

Chesley Taft & Associates LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Jan 10, 2020	SELL	$220.06 - $304.07 $825,004 - $1.14 Million	-3,749 Closed	0 $0
Q3 2019 Oct 07, 2019	SELL	$217.44 - $243.88 $156,121 - $175,105	-718 Reduced 16.07%	3,749 $873,000
Q2 2019 Jul 10, 2019	SELL	$219.29 - $241.72 $16,446 - $18,129	-75 Reduced 1.65%	4,467 $1.05 Million
Q1 2019 Apr 05, 2019	BUY	$216.71 - $338.96 $29,255 - $45,759	135 Added 3.06%	4,542 $1.07 Million
Q4 2018 Jan 07, 2019	BUY	$278.5 - $352.75 $47,345 - $59,967	170 Added 4.01%	4,407 $1.33 Million
Q3 2018 Oct 12, 2018	BUY	$293.51 - $383.83 $13,207 - $17,272	45 Added 1.07%	4,237 $1.5 Million
Q2 2018 Jul 12, 2018	SELL	$257.52 - $306.91 $74,680 - $89,003	-290 Reduced 6.47%	4,192 $1.22 Million
Q1 2018 Apr 11, 2018	BUY	$260.13 - $367.91 $26,013 - $36,791	100 Added 2.28%	4,482 $1.23 Million
Q4 2017 Jan 10, 2018	BUY	$307.64 - $344.58 $38,455 - $43,072	125 Added 2.94%	4,382 $1.4 Million
Q3 2017 Oct 13, 2017	BUY	$281.15 - $329.69 $1.2 Million - $1.4 Million	4,257	4,257 $1.33 Million

1,036

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $22.7B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Chesley Taft & Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Chesley Taft & Associates LLC with notifications on news.